Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies
Two prominent Boston-based biotechs are tying their platform technologies together to see how they can give each other a boost to their respective pipelines.
In a deal announcement shorn of any mention of cash, the gene editing pioneers at Editas have agreed to share their CRISPR platform with BlueRock, a well funded stem cell player — which launched with a $225 million round — looking to play a leading role in the second wave of drug development going on now in the regenerative medicine field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.